Steven Nissen, head of cardiovascular medicine at Cleveland Clinic, wrote in the journal Nature that DDMAC “needs the right to restrict direct-to-consumer advertising during the first two years a drug is marketed and to preview advertising to ensure it is not misleading.” Nissen’s missive, which also advised reevaluating user fees and nixing the last-minute policy change on off-label reprints, was included in a series advising President Obama.
From the March 01, 2009 Issue of MM+M - Medical Marketing and Media
